C2N Diagnostics has partnered with Cambridge Cognition and The Alzheimer's Trust to combine the MHRA-registered PrecivityAD2 blood test with CANTAB digital cognitive assessment and national phlebotomy and MRI infrastructure across the UK. The blood test quantifies Aβ42/Aβ40 and %p-tau217 by high-resolution mass spectrometry to generate an amyloid probability score; company-cited validation data and a Nature Medicine analysis report roughly 90% diagnostic accuracy when paired with digital cognitive testing, against approximately 70% in typical general practice. Earlier and more precise detection shifts Alzheimer's from a late-stage diagnosis to a condition identifiable while intervention windows remain open.
Key Points
- Blood biomarkers plus digital cognition reached roughly 90% diagnostic accuracy
- Typical general practice accuracy cited at approximately 70%
- Integrated UK pathway targets long NHS diagnostic wait times
Longevity Analysis
Amyloid and phosphorylated tau accumulate for a decade or more before memory and executive function measurably decline, which means the decisive question is how early the signal can be read rather than how well symptoms are managed once they appear. A peripheral blood measurement that reflects central nervous system pathology collapses the distance between a routine blood draw and neurological insight, making surveillance feasible at scale rather than confined to specialist centers. Accurate early identification also determines who benefits from sustained metabolic, vascular, and sleep-directed intervention during the years when regenerative capacity in neural tissue is still meaningful.
Original published by LT Wire.